AGITG Innovation Fund
The AGITG Innovation Fund is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations raised through the GI Cancer Institute’s Gutsy Challenge. Expenditure of these funds requires an overall framework that respects their philanthropic origin, and must align with the strategic direction of the AGITG.
Innovation funding will be offered to AGITG members to further AGITG led research. Expenditure decisions will be based on scientific merit and with the intention that they lead to enhancement of the AGITG research program. The successful application will be a proposed AGITG pilot trial that aims to lead on to a larger scale trial to be supported by a peer-reviewed grant source or industry. Applications that do not meet these criteria will not be considered.
An amount of $200,000 has been identified to support a new AGITG pilot trial. The amount and duration of funding for individual projects will be determined as part of the application process.
Applications will be reviewed and prioritised by the Selection Committee (comprising the AGITG Chair, Working Party Chairs and Co‐Chairs, Consumer Advisory Panel Chair and Deputy-Chair, Group Coordinator and Group Statistician), which will provide a recommendation for funding to the Board.
Management of the research funding application process is delegated to the Chief Executive Officer.
Eligible projects must be:
- A pilot phase of a planned AGITG clinical trial.
- Led by registered clinical members of the AGITG. At least one of the applicants listed on the application form must be a current registered member with a minimum of twelve months membership.
- Consistent with the scope and strategic direction of the AGITG research program (locally and internationally).
- Scientifically valid and of high quality with the potential to impact future clinical practice.
- Significant and/or innovative research.
- Feasible within the proposed time frame.
- Able to be linked to future AGITG grant applications or other funding opportunities if required.
- Expected to build capacity and/or collaborations for the AGITG.
Priority will be given to projects that:
- Are clinical in nature
- Are conducted at Participating Institutions of the AGITG
- Build research capacity for the AGITG
- Provide educational opportunity for early-career AGITG researchers
- Have the potential to improve clinical practice standards
- Have the potential to reduce treatment burden on patients and funding systems (and may therefore be unlikely to attract commercial sponsors)
- Demonstrate collaboration between members and Participating Institutions of the AGITG.
It is recommended that research funding applications have a minimum of two (2) current AGITG Trial Principal Investigators from different AGITG Participating Institutions, and that large‐scale project funding applications have a minimum of three (3) current AGITG Trial Principal Investigators from different AGITG Participating Institutions. Principal Investigators should include a mix of AGITG Investigators with a strong track record (relevant to success of future grants) and early-career Investigators who will benefit from mentoring opportunities.
Condition of funding
It is a condition of funding that the AGITG Innovation Funds grant is to be returned to the AGITG if other grant funding is awarded.